Percent changes from baseline are reported by treatment group for plasma levels of hsCRP, IL-6, and D-dimer and the inflammation/coagulation rank composite.
Comparisons between treatment groups at each follow-up visit after adjustment for baseline level are reported in results |
| Figure 1: Percent Change in Biomarkers of Inflammation and Coagulation after Continuing Abacavir/Lamivudine (ABC Group) versus switching to Tenofovir DF/ Emtricitabine (TDF Group). |